Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Wayfair Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Wayfair Inc trades at $104.22 (market cap $14.79B). The key difference: Wayfair Inc is far larger — about 5.2× Dyne Therapeutics Inc. Common Stock's market cap, and Wayfair Inc is trading nearer its 52-week high, Dyne Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Wayfair Inc for 8 Days on average.
| DYN | W | |
|---|---|---|
Market Cap | $2.86B | $14.79B |
Volume | 3,341,579 | 1,870,669 |
Sector | Health | Consumer Cyclical |
52-Week High | $26.78 | $119.05 |
52-Week Low | $14.60 | $57.40 |
Typical Hold Time | 0 Days | 8 Days |
Enterprise Value | $2.18B | $17.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Wayfair (W) trades at $107.99, up 1.74% on the day, with a bullish technical signal from moving averages. The company reported revenue of $12.46B in 2025 but a net loss of $313M, with a negative net income margin of -2.49%. Analyst consensus is positive with a $114.13 price target, and recent news highlights brand expansion and upcoming Q3 2026 earnings.
The outlook for Wayfair hinges on improving profitability amid competitive pressures. While revenue growth is steady, persistent losses and high debt-to-asset ratio of 95.11% pose risks. The stock offers upside to the consensus target but requires monitoring of cost management and consumer spending trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
